Precision BioSciences Advances PBGENE-HBV to Phase 1 Trial for Chronic Hepatitis B Treatment
• Precision BioSciences received approval for its Clinical Trial Application for PBGENE-HBV, a gene editing therapy for chronic hepatitis B.
• The Phase 1 clinical program for PBGENE-HBV has commenced in Moldova, with patient screening underway and clinical data expected in 2025.
• PBGENE-HBV is designed to eliminate cccDNA and inactivate integrated HBV DNA, addressing the root cause of viral persistence in chronic hepatitis B.
• Precision BioSciences anticipates submitting an IND or CTA for PBGENE-3243, targeting m.3243-associated mitochondrial disease, in 2025.
© Copyright 2025. All Rights Reserved by MedPath